Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk N-acetylcysteine  Galindo-Andúgar et al.  LATE TREATMENT Is late treatment with N-acetylcysteine beneficial for COVID-19? Retrospective 378 patients in Spain (March - April 2020) Lower mortality with N-acetylcysteine (p=0.05) c19early.org Galindo-Andúgar et al., Revista Clínic.., Jul 2023 Favors N-acetylcysteine Favors control

Impact of N-Acetylcysteine in the mortality of patients hospitalized with COVID-19: a retrospective cohort study

Galindo-Andúgar et al., Revista Clínica Española, doi:10.1016/j.rceng.2023.07.006
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
13th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000034 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 378 hospitalized patients in Spain, showing lower mortality with N-acetylcysteine treatment.
risk of death, 43.0% lower, OR 0.57, p = 0.05, treatment 199, control 179, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Galindo-Andúgar et al., 21 Jul 2023, retrospective, Spain, peer-reviewed, median age 73.3, 6 authors, study period March 2020 - April 2020.
This PaperN-acetylcys..All
{ 'DOI': '10.1016/j.rceng.2023.07.006', 'ISSN': ['2254-8874'], 'URL': 'http://dx.doi.org/10.1016/j.rceng.2023.07.006', 'alternative-id': ['S2254887423000929'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Impact of N-Acetylcysteine in the mortality of patients hospitalized with ' 'COVID-19: a retrospective cohort study'}, { 'label': 'Journal Title', 'name': 'journaltitle', 'value': 'Revista Clínica Española (English Edition)'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/j.rceng.2023.07.006'}, { 'label': 'CrossRef DOI link to the associated document', 'name': 'associatedlink', 'value': 'https://doi.org/10.1016/j.rce.2023.07.002'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2023 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna ' '(SEMI). All rights reserved.'}], 'author': [ {'affiliation': [], 'family': 'Galindo-Andúgar', 'given': 'M.A.', 'sequence': 'first'}, {'affiliation': [], 'family': 'Arias Arias', 'given': 'Á.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Alfonso García Guerra', 'given': 'J.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fernández Visier', 'given': 'I.', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Manuel Fernández Ibáñez', 'given': 'J.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bellido Maldonado', 'given': 'A.', 'sequence': 'additional'}], 'container-title': 'Revista Clínica Española (English Edition)', 'container-title-short': 'Revista Clínica Española (English Edition)', 'content-domain': { 'crossmark-restriction': True, 'domain': ['elsevier.es', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2023, 7, 21]], 'date-time': '2023-07-21T07:38:40Z', 'timestamp': 1689925120000}, 'deposited': { 'date-parts': [[2023, 7, 27]], 'date-time': '2023-07-27T13:54:51Z', 'timestamp': 1690466091000}, 'indexed': {'date-parts': [[2023, 7, 28]], 'date-time': '2023-07-28T04:13:26Z', 'timestamp': 1690517606143}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2023, 7]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T00:00:00Z', 'timestamp': 1688169600000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2254887423000929?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2254887423000929?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'prefix': '10.1016', 'published': {'date-parts': [[2023, 7]]}, 'published-print': {'date-parts': [[2023, 7]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.1096/fj.202001807', 'article-title': 'Rationale for the use of N-acetylcysteine in both prevention and ' 'adjuvant therapy of COVID-19', 'author': 'De Flora', 'doi-asserted-by': 'crossref', 'first-page': '13185', 'journal-title': 'FASEB J', 'key': '10.1016/j.rceng.2023.07.006_bib0005', 'volume': '34', 'year': '2020'}, { 'DOI': '10.1007/s10930-020-09935-8', 'article-title': 'Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) ' 'infection: a review', 'author': 'Suhail', 'doi-asserted-by': 'crossref', 'first-page': '644', 'journal-title': 'Protein J', 'key': '10.1016/j.rceng.2023.07.006_bib0010', 'volume': '39', 'year': '2020'}, { 'DOI': '10.1016/j.toxrep.2020.06.003', 'article-title': 'Reactive oxygen species as an initiator of toxic innate immune ' 'responses in retort to SARS-CoV-2 in an ageing population, consider ' 'N-acetylcysteine as early therapeutic intervention', 'author': 'Nasi', 'doi-asserted-by': 'crossref', 'first-page': '768', 'journal-title': 'Toxicol Rep', 'key': '10.1016/j.rceng.2023.07.006_bib0015', 'volume': '7', 'year': '2020'}, { 'article-title': 'Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine ' 'storm in COVID-19: review of current evidence', 'author': 'Mohanty', 'first-page': '2802', 'journal-title': 'Eur Rev Med Pharmacol Sci', 'key': '10.1016/j.rceng.2023.07.006_bib0020', 'volume': '25', 'year': '2021'}, { 'DOI': '10.3389/fchem.2021.685196', 'article-title': 'Changes in glycolytic pathway in SARS-COV 2 infection and their ' 'importance in understanding the severity of COVID-19', 'author': 'Santos', 'doi-asserted-by': 'crossref', 'journal-title': 'Front Chem', 'key': '10.1016/j.rceng.2023.07.006_bib0025', 'volume': '9', 'year': '2021'}, { 'DOI': '10.1016/j.mehy.2020.109862', 'article-title': 'N-Acetylcysteine: a potential therapeutic agent for SARS-CoV-2', 'author': 'Poe', 'doi-asserted-by': 'crossref', 'journal-title': 'Med Hypotheses', 'key': '10.1016/j.rceng.2023.07.006_bib0030', 'volume': '143', 'year': '2020'}, { 'DOI': '10.3949/ccjm.87a.ccc046', 'article-title': 'What is the role of supplementation with ascorbic acid, zinc, vitamin ' 'D, or N-acetylcysteine for prevention or treatment of COVID-19?', 'author': 'Bauer', 'doi-asserted-by': 'crossref', 'journal-title': 'Cleve Clin J Med', 'key': '10.1016/j.rceng.2023.07.006_bib0035', 'year': '2020'}, { 'DOI': '10.3390/v13030425', 'article-title': 'The combination of bromelain and acetylcysteine (BromAc) ' 'synergistically inactivates SARS-CoV-2', 'author': 'Akhter', 'doi-asserted-by': 'crossref', 'first-page': '425', 'journal-title': 'Viruses', 'key': '10.1016/j.rceng.2023.07.006_bib0040', 'volume': '13', 'year': '2021'}, { 'DOI': '10.3390/antiox10020272', 'article-title': 'Potential role of antioxidant and anti-inflammatory therapies to ' 'prevent severe SARS-Cov-2 complications', 'author': 'Fratta Pasini', 'doi-asserted-by': 'crossref', 'first-page': '272', 'journal-title': 'Antioxidants (Basel)', 'key': '10.1016/j.rceng.2023.07.006_bib0045', 'volume': '10', 'year': '2021'}, { 'DOI': '10.5501/wjv.v10.i2.34', 'article-title': 'Bottom-up analysis of emergent properties of N-acetylcysteine as an ' 'adjuvant therapy for COVID-19', 'author': 'Dominari', 'doi-asserted-by': 'crossref', 'first-page': '34', 'journal-title': 'World J Virol', 'key': '10.1016/j.rceng.2023.07.006_bib0050', 'volume': '10', 'year': '2021'}, { 'DOI': '10.2147/TCRM.S273700', 'article-title': 'N-Acetylcysteine to combat COVID-19: an evidence review', 'author': 'Shi', 'doi-asserted-by': 'crossref', 'first-page': '1047', 'journal-title': 'Ther Clin Risk Manag', 'key': '10.1016/j.rceng.2023.07.006_bib0055', 'volume': '16', 'year': '2020'}, { 'DOI': '10.1155/2021/9949453', 'article-title': 'N-Acetylcysteine: a review of clinical usefulness (an old drug with new ' 'tricks)', 'author': 'Schwalfenberg', 'doi-asserted-by': 'crossref', 'journal-title': 'J Nutr Metab', 'key': '10.1016/j.rceng.2023.07.006_bib0060', 'volume': '2021', 'year': '2021'}, { 'DOI': '10.1016/j.rce.2020.07.003', 'article-title': 'Clinical characteristics of patients hospitalized with COVID-19 in ' 'Spain: Results from the SEMI-COVID-19 Registry', 'author': 'Casas-Rojo', 'doi-asserted-by': 'crossref', 'first-page': '480', 'journal-title': 'Rev Clin Esp', 'key': '10.1016/j.rceng.2023.07.006_bib0065', 'volume': '220', 'year': '2020'}, { 'DOI': '10.1183/16000617.0152-2021', 'article-title': 'Asthma and COVID-19: an update', 'author': 'Adir', 'doi-asserted-by': 'crossref', 'journal-title': 'Eur Respir Rev', 'key': '10.1016/j.rceng.2023.07.006_bib0070', 'volume': '30', 'year': '2021'}, { 'DOI': '10.1183/13993003.03142-2020', 'article-title': 'The impact of COVID-19 on patients with asthma', 'author': 'Izquierdo', 'doi-asserted-by': 'crossref', 'journal-title': 'Eur Respir J', 'key': '10.1016/j.rceng.2023.07.006_bib0075', 'volume': '57', 'year': '2021'}, { 'DOI': '10.1080/23744235.2021.1945675', 'article-title': 'N-acetyl-cysteine reduces the risk for mechanical ventilation and ' 'mortality in patients with COVID-19 pneumonia: a two-center ' 'retrospective cohort study', 'author': 'Assimakopoulos', 'doi-asserted-by': 'crossref', 'first-page': '847', 'journal-title': 'Infect Dis (Lond)', 'key': '10.1016/j.rceng.2023.07.006_bib0080', 'volume': '53', 'year': '2021'}, { 'DOI': '10.1177/00368504221074574', 'article-title': 'Use of N-Acetylcysteine at high doses as an oral treatment for patients ' 'hospitalized with COVID-19', 'author': 'Izquierdo', 'doi-asserted-by': 'crossref', 'journal-title': 'Sci Prog', 'key': '10.1016/j.rceng.2023.07.006_bib0085', 'volume': '105', 'year': '2022'}, { 'DOI': '10.1096/fj.202100560R', 'article-title': 'Disruption of disulfides within RBD of SARS-CoV-2 spike protein ' 'prevents fusion and represents a target for viral entry inhibition by ' 'registered drugs', 'author': 'Manček-Keber', 'doi-asserted-by': 'crossref', 'journal-title': 'FASEB J', 'key': '10.1016/j.rceng.2023.07.006_bib0090', 'volume': '35', 'year': '2021'}, { 'DOI': '10.3390/cells11203313', 'article-title': 'Inhibition of the cell uptake of delta and omicron SARS-CoV-2 ' 'pseudoviruses by N-acetylcysteine irrespective of the oxidoreductive ' 'environment', 'author': 'La Maestra', 'doi-asserted-by': 'crossref', 'first-page': '3313', 'journal-title': 'Cells', 'key': '10.1016/j.rceng.2023.07.006_bib0095', 'volume': '11', 'year': '2022'}, { 'DOI': '10.3390/ijms232314518', 'article-title': 'N-acetylcysteine reduces inflammasome activation induced by SARS-CoV-2 ' 'proteins in vitro', 'author': 'Milara', 'doi-asserted-by': 'crossref', 'first-page': '14518', 'journal-title': 'Int J Mol Sci', 'key': '10.1016/j.rceng.2023.07.006_bib0100', 'volume': '23', 'year': '2022'}, { 'DOI': '10.1093/cid/ciaa1443', 'article-title': 'Double-blind, randomized, placebo-controlled trial with ' 'N-acetylcysteine for treatment of severe acute respiratory syndrome ' 'caused by coronavirus disease 2019 (COVID-19)', 'author': 'de Alencar', 'doi-asserted-by': 'crossref', 'first-page': 'e736', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/j.rceng.2023.07.006_bib0105', 'volume': '72', 'year': '2021'}, { 'DOI': '10.1007/s43440-021-00296-2', 'article-title': 'A pilot study on intravenous N-acetylcysteine treatment in patients ' 'with mild-to-moderate COVID19-associated acute respiratory distress ' 'syndrome', 'author': 'Taher', 'doi-asserted-by': 'crossref', 'first-page': '1650', 'journal-title': 'Pharmacol Rep', 'key': '10.1016/j.rceng.2023.07.006_bib0110', 'volume': '73', 'year': '2021'}, { 'DOI': '10.1016/j.jinf.2021.07.003', 'article-title': 'N-acetylcysteine for the treatment of COVID-19 among hospitalized ' 'patients', 'author': 'Avdeev', 'doi-asserted-by': 'crossref', 'first-page': '94', 'journal-title': 'Journal of Infection', 'key': '10.1016/j.rceng.2023.07.006_bib0115', 'volume': '84', 'year': '2022'}, { 'DOI': '10.1016/j.jiph.2022.11.009', 'article-title': 'N-acetylcysteine for prevention and treatment of COVID-19: current ' 'state of evidence and future directions', 'author': 'Izquierdo-Alonso', 'doi-asserted-by': 'crossref', 'first-page': '1477', 'journal-title': 'J Infect Public Health', 'key': '10.1016/j.rceng.2023.07.006_bib0120', 'volume': '15', 'year': '2022'}, { 'article-title': 'N-acetylcysteine efficacy in patients hospitalized with COVID-19 ' 'pneumonia: a systematic review and meta-analysis', 'author': 'Paraskevas', 'first-page': '41', 'journal-title': 'Rom J Intern Med', 'key': '10.1016/j.rceng.2023.07.006_bib0125', 'volume': '61', 'year': '2023'}, { 'DOI': '10.1097/JCMA.0000000000000869', 'article-title': 'Is N-acetylcysteine effective in treating patients with coronavirus ' 'disease 2019? A meta-analysis', 'author': 'Chen', 'doi-asserted-by': 'crossref', 'first-page': '274', 'journal-title': 'J Chin Med Assoc', 'key': '10.1016/j.rceng.2023.07.006_bib0130', 'volume': '86', 'year': '2023'}, { 'DOI': '10.1002/jmv.28393', 'article-title': 'Evaluation the efficacy and safety of N-acetylcysteine inhalation spray ' 'in controlling the symptoms of patients with COVID-19: an open-label ' 'randomized controlled clinical trial', 'author': 'Panahi', 'doi-asserted-by': 'crossref', 'journal-title': 'J Med Virol', 'key': '10.1016/j.rceng.2023.07.006_bib0135', 'volume': '95', 'year': '2023'}, { 'key': '10.1016/j.rceng.2023.07.006_bib0140', 'unstructured': 'https://clinicaltrials.gov/ct2/results?term=acetylcysteine+%20AND%20+Covid&Search. ' '(Accessed 19 June 2023).'}], 'reference-count': 28, 'references-count': 28, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2254887423000929'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'Impact of N-Acetylcysteine in the mortality of patients hospitalized with COVID-19: a ' 'retrospective cohort study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit